News

Capitol Hill
Save the Orphan Drug Tax Credit!
Earlier this month, House Republicans proposed eliminating the orphan drug tax credit, which was originally passed as part of the Orphan Drug Act in 1983 as an incentive for drug makers to spur the creation of medicines for rare diseases....
Read More
ARC Giving Tuesday
Contribute to a Cure. Join our Campaign #10x10x10
Each day we are adding another critical reason for you to ask 10 friends to donate 10 dollars to the Amyloidosis Research Consortium.   Day 10: Your Partnership ARC is heavily reliant on donations and the fundraising efforts of the amyloidosis...
Read More
Gene Silencing Holds Promise for Treating Hereditary ATTR Amyloidosis
A novel therapeutic approach which exploits the normal biological process of gene silencing, or RNA interference (RNAi), is continuing to show promise as a potential treatment for hereditary ATTR (hATTR) amyloidosis. Results presented recently at the 1st European ATTR Amyloidosis...
Read More
Mazen Hanna
Physician Spotlight: Dr. Mazen Hanna
Dr. Mazen Hanna is a cardiologist and current co-director of the Amyloidosis Program at the Cleveland Clinic alongside hematologist, Dr. Jason Valent. He has been a member of the heart failure and cardiac transplant unit in the department of cardiovascular...
Read More
Northern California Support Group and Patient’s Day Hosted by Prothena
The Northern California Amyloidosis Support Group which meets quarterly every year, held their 14th annual anniversary meeting in July in South San Francisco.  The event was hosted by the team at Prothena and was a very successful Patient’s Day event...
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org

ARC is a 501(c)(3) nonprofit organization